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Abstract
Background: Intravenous pulse methylprednisolone (MP) is commonly included in the management of severe
ANCA associated vasculitis (AAV) despite limited evidence of benefit. We aimed to evaluate outcomes in patients
who had, or had not received MP, along with standard therapy for remission induction in severe AAV.
Methods: We retrospectively studied 114 consecutive patients from five centres in Europe and the United States
with a new diagnosis of severe AAV (creatinine > 500 μmol/L or dialysis dependency) and that received standard
therapy (plasma exchange, cyclophosphamide and high-dose oral corticosteroids) for remission induction with or
without pulse MP between 2000 and 2013. We evaluated survival, renal recovery, relapses, and adverse events over
the first 12 months.
Results: Fifty-two patients received pulse MP in addition to standard therapy compared to 62 patients that did not.
There was no difference in survival, renal recovery or relapses. Treatment with MP associated with higher risk of
infection during the first 3 months (hazard ratio (HR) 2.7, 95%CI [1.4–5.3], p = 0.004) and higher incidence of diabetes
(HR 6.33 [1.94–20.63], p = 0.002), after adjustment for confounding factors.
Conclusions: The results of this study suggest that addition of pulse intravenous MP to standard therapy for remission
induction in severe AAV may not confer clinical benefit and may be associated with more episodes of infection and
higher incidence of diabetes.
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Background
The antineutrophil cytoplasmic antibody (ANCA) associated
vasculitides (AAV) are a group of systemic, autoimmune, in-
flammatory conditions, that include granulomatosis with
polyangiitis (GPA), microscopic polyangiitis (MPA) and its
renal limited variant (renal limited vasculitis; RLV). They are
characterised by necrotising inflammation affecting small to
medium blood vessels leading to end organ damage [1].
Severity in AAV ranges from localised disease to se-
vere involvement, the latter defined by the presence of
life threatening manifestations that usually include rap-
idly progressive glomerulonephritis with a requirement
for renal replacement therapy. Treatment in AAV is dic-
tated by severity [2]. The MEPEX trial compared plasma
exchange (PEX) to intravenous pulse methylpredniso-
lone (MP) over 3 days in addition to oral cyclophospha-
mide and high dose oral corticosteroids for induction of
remission in severe AAV and showed improved renal
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recovery in the PEX arm [3]. Since then, the use of PEX
for induction of remission in severe AAV has become
commonplace, albeit on a recent follow-up analysis the
long-term benefit of PEX has been less clear [4]. How-
ever, many clinicians also routinely use MP prior to
commencing high dose oral corticosteroids in addition
to PEX and cyclophosphamide.
Use of high dose corticosteroids, including MP, must be
balanced with their extensive side effect profile and signifi-
cant resultant toxicity. Several studies in AAV have sug-
gested that corticosteroids are directly linked to an
increased risk of infection [5–9] whilst weight gain, hyper-
glycaemia and new onset diabetes mellitus represent im-
portant metabolic adverse effects of corticosteroids with
significant consequences for patients [5, 9–11]. Further-
more, infection remains the most common cause of death
in the first 12months following diagnosis of AAV [12, 13].
A single-centre analysis from 1989 of a heterogeneous
cohort of patients with acute crescentic rapidly progres-
sive glomerulonephritis of various aetiologies suggested
better outcome in patients treated with MP [14]. How-
ever, since then there have been no randomised con-
trolled trials or observational studies in AAV patients
examining whether the use of MP confers benefit for pa-
tients, or indeed whether it is associated with harm.
Given the paucity of information in the literature, we
sought to determine whether the addition of intravenous
pulse MP to standard therapy for induction of remission
in severe AAV is associated with an improvement in sur-
vival, renal recovery or relapse within the first year after
diagnosis and examine any possible association with
treatment related adverse events such as infection,
leukopenia and new onset diabetes mellitus.
Methods
Patients
We retrospectively analysed outcomes of consecutive pa-
tients that presented in five renal centres in Europe and
the United States with a new diagnosis of severe AAV
and that received standard therapy for induction of re-
mission with or without intravenous pulse MP between
2000 and 2013.
Definition of severe AAV was based on clinical features
in keeping with a diagnosis of AAV (granulomatosis with
polyangiitis, microscopic polyangiitis or renal limited vas-
culitis) and either positive ANCA serology or characteris-
tic features on biopsy, as well as a creatinine greater than
500 μmol/L or dialysis dependency at presentation. Pa-
tients were classified based on ANCA specificity (PR3 or
MPO) rather than clinical diagnosis as accumulating evi-
dence suggests that ANCA specificity affects the pheno-
type of clinical disease, as well as the patient’s initial
response to remission-induction therapy and relapse risk
[15]. Patients had to have received PEX, pulse or
continuous oral cyclophosphamide and high-dose oral
corticosteroids with or without intravenous pulse MP for
inclusion in the study. We excluded patients that received
rituximab or a combination of rituximab and cyclophos-
phamide for induction of remission. Intravenous pulse
MP use was dependent on physician choice. Use of intra-
venous pulse MP across the 5 study centres is shown in
Additional file 1: Table S1.
Data was collected retrospectively from electronic and
paper medical records. Birmingham Vasculitis Activity
Score (BVAS) was calculated retrospectively. We col-
lected data on baseline descriptive and treatment charac-
teristics as well as pre-defined outcomes over the first
12 months post AAV diagnosis and commencement of
therapy as follows: survival, renal recovery, relapses, in-
fections, leukopenic episodes (white cell count < 4 × 109/
L) and diagnosis of new onset diabetes mellitus.
Renal recovery at 12 months was defined as achieve-
ment of independence from renal replacement therapy
and no further requirement for renal replacement ther-
apy by 12 months for patients that required dialysis at
presentation, or, improvement in renal function and no
requirement for renal replacement therapy by 12months
for patients that presented with creatinine greater than
500 μmol/L but were not dialysis dependent at presenta-
tion. We also collected data on duration of dialysis for
patients that were dialysis dependent at presentation,
and creatinine at 12 months. When examining creatinine
at 12 months we excluded patients that were on dialysis.
Retrospective clinical information regarding episodes of
infection was obtained by examining hospital medical re-
cords. All significant documented infections (requiring
antibiotic treatment or admission to hospital) were in-
cluded. Severe infections were defined as those requiring
hospital admission, prolongation of hospital admission
or treatment with intravenous antibiotics. We defined
new onset diabetes as a requirement for treatment with
either oral hypoglycaemic agents or insulin in a patient
not diagnosed with diabetes mellitus prior to commen-
cing induction treatment for AAV.
Data presentation
Data was analysed using SPSS Version 21 (Armonk, NY:
IBM Corp.), GraphPad Prism Version 5 (GraphPad Soft-
ware, San Diego, California) and R (R Foundation for
Statistical Computing, Vienna, Austria). Baseline charac-
teristics, renal recovery and relapses between MP treated
and non-MP treated patients were compared using the
Chi-square test, or Fisher’s exact test where appropriate,
for categorical variables, and the Mann Whitney U test
for non-parametric continuous variables. Kaplan-Meier
curve analysis was employed to examine differences in
survival, time to infection, severe infection, leukopenia
and new onset diabetes in the two groups. Patients with
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pre-existing diabetes were excluded from the analysis for
new onset diabetes. Log rank was used for statistical
comparisons of Kaplan-Meier curves.
Proportional hazards analysis was used to detect sig-
nificant predictors of time to first infection, severe infec-
tion, new onset diabetes and survival. Time dependent
covariates were entered in models in a time dependent
fashion. Cyclophosphamide dose and oral prednisolone
dose were entered as segmented time dependent covari-
ates as follows: cyclophosphamide dose at 2 weeks, 1
month, 3 months and 6months and oral prednisolone
dose at 1 week, 2 weeks, 1 month, 3 months, 6 months
and 12 months. Multivariable proportional hazards
models were constructed to control for relevant con-
founders. Covariates with a p value ≤0.1 on univariable
analysis were included in the models. A p value of less
than 0.05 was considered statistically significant for all
analyses.
Results
Baseline and treatment characteristics
Baseline characteristics for 114 patients that presented
with severe AAV and fulfilled the inclusion criteria for
the study are shown in Table 1. Fifty-two patients re-
ceived intravenous pulse MP in addition to standard
therapy for induction of remission compared to 62 pa-
tients that did not. There were no differences in age or
gender between groups but there was a statistically sig-
nificant difference in ethnicity. Clinical characteristics
and markers of severity such as creatinine at baseline,
percentage of glomeruli with crescents on initial renal
biopsy, and BVAS score were comparable except for pa-
tients that received MP were more likely to have had
concomitant pulmonary haemorrhage but less likely to
have had other lung or ENT involvement (Table 1).
The median dose of MP was 1.5 g (IQR: 1.5–1.9)
administered in 3 intravenous pulses over 3 days. Pa-
tients treated with MP received a lower number of PEX
cycles compared to non-MP patients and a lower dose
of total cyclophosphamide and total oral prednisolone
dose over the first 12 months following diagnosis (Table
1). Cumulative dose of cyclophosphamide and oral pred-
nisolone at different time-points during the study is
shown in Additional file 1: Table S2.
Survival, renal recovery and relapses
There was no difference in overall survival between pa-
tients treated with MP and patients that did not receive
MP (Fig. 1). At the 3 month time point 94.2% of MP
treated patients and 91.9% of non-MP treated patients
were alive (p = 0.726), whilst at the end of the 12month
follow up those figures were 84.6 and 82.3% respectively
(p = 0.737). Similarly, there was no difference in renal re-
covery with 57.7% of MP treated patients and 66.1% of
non-MP treated patients having achieved renal recovery
by 12 months (p = 0.355), although creatinine at 12
months (excluding patients on dialysis) was higher in
the MP treated group (MP: 207 μmol/L, IQR 142–269;
non-MP: 143 μmol/L, IQR 118–179; p = 0.008). In
addition, there was no difference in time to renal
Table 1 Baseline and treatment characteristics
Overall Methylprednisolone treated No methylprednisolone P value*
Number of patients 114 52 62
Age, years 62 (54–72) 60 (47–72) 62 (56–72) 0.166
No. of men/women 77/37 35/17 42/20 0.961
No. of Caucasian/Non-Caucasian 100/14 39/13 61/1 < 0.001
No. of PR3 positive (%) 65 (57.0) 27 (51.9) 38 (61.3) 0.314
No. with pulmonary haemorrhage (%) 26 (22.8) 18 (34.6) 8 (12.9) 0.006
No. with other lung disease (%) 59 (51.8) 20 (38.5) 39 (62.9) 0.009
No. with ENT disease (%) 49 (43.0) 15 (28.8) 34 (54.8) 0.005
BVAS score 18 (12–20) 16 (12–22) 20 (14–20) 0.852
Glomeruli with crescents (%) 60.0 (34.5–80) 62.5 (33.0–77.0) 58.5 (37.5–80.0) 0.666
Baseline Creatinine, μmol/L 619 (530–790) 594 (506–787) 647 (547–790) 0.189
Plasma Exchange, No. of treatments 7 (6–9) 7 (5–7) 7 (7–10) < 0.001†
MP dose, g – 1.5 (1.5–1.9) – –
Total Cyclophosphamide dose, g 7.2 (4.6–9.8) 5.2 (3.6–9.4) 8.6 (6.4–10.5) 0.005
Total Oral Prednisolone dose (12 months), g 5.5 (3.9–6.8) 4.0 (3.9–5.3) 6.8 (5.5–7.0) < 0.001
Values reported as median (IQR)
*Comparison between MP and non-MP treated patients
† Median value was the same in MP and non-MP treated patients but in MP group 3 values were greater than the median compared to 29 values greater than
the median in the non-MP group
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replacement therapy independence amongst dialysis
dependent patients at diagnosis, between MP and
non-MP treated patients (MP: 30 days, IQR 14–60;
non-MP: 30 days, IQR 12–60; p = 1.00). Relapses were
similar in the two groups with 11.5 and 8.1% of MP and
non-MP treated patients having relapsed by 12months
respectively (p = 0.545).
Adverse events
Infection and leukopenia
There was no difference in episodes of leukopenia be-
tween MP and non-MP treated patients (Fig. 2). Treat-
ment with MP however was associated with more
episodes of infection overall as well as more severe in-
fections. This difference was confined to the first 3
months following diagnosis and commencement of ther-
apy as can be seen in Fig. 3, with 44.2 and 24.2% of MP
and non-MP treated patients respectively having had an
episode of infection by 3 months. Similarly, 36.5% of MP
treated patients compared to 19.4% of non-MP treated
patients had an episode of severe infection by the end of
3 months (Fig. 3). There was no difference in the onset
of new infections or that of new severe infections be-
tween 3 and 12months (Additional file 1: Figures S1B
and S1D). Therefore, multivariable proportional hazards
models were constructed to determine independent pre-
dictors of infection and severe infection by 3 months.
Variables associated with infection and severe infection
by 3months on univariable analysis are listed in Table 2.
When these factors were added in multivariable
proportional hazards models, MP treatment remained a
significant predictor of infection overall as well as severe
infection at 3 months (Table 2). Furthermore the dose of
MP delivered was also a significant and independent
predictor of infection (hazard ratio (HR) 1.5, 95% CI
1.1–1.9 per gram of MP; p = 0.010) and severe infection
(HR 1.44, 95% CI 1.03–2.00 per gram of MP; p = 0.034)
at 3 months (Additional file 1: Table S3).
Finally, infection had a significant bearing on survival.
Patients that had an infection during the first 3 months
had a hazard ratio of 5.58 (95% CI 1.99–16.65; p = 0.001)
for death by 12 months after adjusting for possible con-
founders (Table 3).
New onset diabetes
We observed an increased incidence of diabetes mellitus
amongst MP treated patients. By 12months 26.9% of MP
treated patients developed diabetes compared to 6.5% of
non-MP treated patients with most cases occurring within
the first month following diagnosis and commencement
of therapy as shown in Fig. 4. Treatment with MP was the
only factor that was significantly associated with new on-
set diabetes (HR 5.1 [1.7–15.7], p = 0.004). Furthermore,
the dose of MP delivered was also a significant predictor
of new onset diabetes (HR 1.8, 95% CI 1.2–2.7 per gram
of MP; p = 0.003). To account for potential confounding
factors we also controlled for the effect of age, ethnicity
and cumulative dose of oral prednisolone in multivariable
proportional hazards models. The association between
Fig. 1 Time to survival by 12months was examined by Kaplan-Meier
curve analysis. Survival for patients that received MP is shown in the
dashed line and that for non-MP treated patients in the solid line
Fig. 2 Time to leukopenia by 12 months was examined by Kaplan-
Meier curve analysis. Time to leukopenia for patients that received
MP is shown in the dashed line and that for non-MP treated
patients in the solid line
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MP use and MP dose with increased incidence of diabetes
mellitus remained significant (Table 4).
Discussion
This retrospective analysis of a large cohort of incident pa-
tients who presented with severe AAV in five large vascu-
litis centres in Europe and the United States suggests that
the addition of intravenous pulse MP to standard induc-
tion of remission therapy with cyclophosphamide, plasma
exchange and high-dose oral corticosteroids may not con-
fer any benefit in terms of improving patient outcomes
and may increase patient harm.
We found no difference in overall survival, renal re-
covery or relapses by 12months between patients that
received MP in addition to standard therapy and those
that did not receive MP, despite the two groups being
well balanced in terms of age, ANCA specificity and
markers of severity such as BVAS score, presenting cre-
atinine and percentage of glomeruli with crescents on
renal biopsy. In addition, treatment with MP, as well as
the total dose of MP delivered, was associated with a
higher and earlier onset of infection and severe infection
episodes, and a higher incidence of diabetes mellitus in
the MP treated patients that were particularly prominent
in the first month following commencement of therapy.
There were significant differences between the MP
treated patients and those that did not receive MP. In
addition, the proportion of patients that received MP
differed amongst the study centres. We carefully con-
trolled for baseline and treatment characteristics in our
multivariable analyses. However, it is possible that
between-centre differences remain that may not have
Fig. 3 Time to infection overall (left panel) and severe infection (right panel) by 12 months was examined by Kaplan-Meier curve analysis. Time to
infection is shown in the dashed line for patients that received MP and in the solid line for non-MP treated patients. The difference in infection is
confined to the first 3 months as can be seen by the curves being essentially parallel from 3months onwards
Table 2 Factors associated with infection at 3 months on univariable and multivariable proportional hazards analysis
Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value
(A) Time to infection at 3 months
Treatment with MP 2.2 (1.1–4.2) 0.018 2.7 (1.4–5.3) 0.004
Leukopenia preceding infection 3.6 (1.6–8.0) 0.001 4.3 (1.9–9.5) < 0.001
Dose of oral prednisolone, g 5.4 (1.1–27.3) 0.043 8.5 (1.4–53.2) 0.022
(B) Time to severe infection at 3 months
Treatment with MP 2.1 (1.0–4.3) 0.043 2.9 (1.3–6.6) 0.010
Leukopenia preceding infection 4.8 (2.1–10.9) < 0.001 5.6 (2.4–13.0) < 0.001
Dose of oral prednisolone, g 9.2 (1.5–54.7) 0.015 17.9 (1.9–164.5) 0.011
BVAS score 1.1 (1.0–1.2) 0.005 1.1 (1.0–1.2) 0.131
Lung involvement 1.9 (0.9–3.9) 0.096 1.2 (0.5–3.1) 0.678
Dose of oral prednisolone was entered as a segmented time dependent variable as follows: dose at 1 week, 2 weeks, 1 month and 3months
HR = hazard ratio, CI = confidence intervals
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been fully controlled for by our analyses. This together
with the retrospective nature of data collection repre-
sents one of the main limitations of this study.
MP treated patients were more likely to have had pul-
monary haemorrhage at presentation which suggests a
bias towards physician choice of therapy amongst pa-
tients that are perhaps perceived to have more severe
disease, although there was no difference in the severity
of renal disease, or overall BVAS score between the two
groups.
There were significant differences in the standard
treatment that patients received, with MP treated pa-
tients receiving a lower load in terms of number of
plasma exchange treatments, total dose of cyclophospha-
mide and total dose of oral prednisolone over the first
12 months likely reflecting differences between treating
physicians and treating centres. A greater proportion of
non-MP patients received oral daily instead of pulsed
cyclophosphamide and this accounted for the higher cu-
mulative cyclophosphamide dose seen in non-MP
treated patients. To account for the treatment differ-
ences between MP and non-MP treated patients we
carefully controlled for cumulative cyclophosphamide
and oral prednisolone dose by analysing these variables
in a time-dependent manner as segmented
time-dependent covariates using the time-intervals tabu-
lated in Additional file 1: Table S2.
Both the use of MP and the cumulative oral prednisol-
one dose were independent predictors of risk of infec-
tion and risk of severe infection by 3 months.
Importantly however, the cumulative oral prednisolone
dose was comparable between MP and non-MP treated
patients up until 3 months (Additional file 1: Table S2)
indicating that the effect of MP use on the risk of infec-
tion was separate and additional to that associated with
the cumulative oral prednisolone dose received. In
addition, MP treated patients had a higher incidence of
infection as well as diabetes mellitus nearer the time of
presentation and MP treatment, suggesting validity of
our results. This observation also suggests that the peak
of steroid dose early on in the treatment phase may be
important in the development of treatment associated
complications.
In systemic lupus erythematosus (SLE), a higher cu-
mulative dose of intravenous MP is associated with more
infections and the majority of infections occur within
the first month following treatment [16]. Systemic pa-
rameters present at the time of diagnosis may also com-
pound this effect. It has been shown for example that
Table 3 Multivariable proportional hazards model for survival at
12 months
Hazard ratio
(95% Confidence Interval)
P value
Age, years 1.07 (1.03–1.12) 0.001
Infection by 3 months 5.58 (1.99–15.65) 0.001
Lung involvement 3.53 (1.21–10.31) 0.021
Cyclophosphamide dose, g 0.93 (0.69–1.26) 0.648
Treatment with MP 0.75 (0.28–2.01) 0.564
Dose of cyclophosphamide was entered in the model as a segmented time
dependent covariate as follows: dose at 2 weeks, 1 month, 3 months, 6 months
and 12 months
Infection during the first 3 months was added as a time dependent covariate
indicating whether such an infection had occurred
Fig. 4 Time to new onset diabetes by 12 months was examined by
Kaplan-Meier curve analysis and is shown in the dashed line for
patients that received MP and in the solid line for patients that were
not treated with MP
Table 4 Multivariable proportional hazards model for incidence
of diabetes mellitus
Hazard ratio
(95% Confidence Interval)
P value
(A) Treatment with MP
Age, years 0.99 (0.96–1.02) 0.621
Ethnicity 1.55 (0.42–5.70) 0.512
Dose of oral prednisolone, g 2.26 (0.47–10.86) 0.310
Treatment with MP 6.33 (1.94–20.63) 0.002
(B) Dose of MP
Age, years 0.99 (0.96–1.02) 0.587
Ethnicity 1.37 (0.37–5.08) 0.640
Dose or oral prednisolone, g 1.85 (0.41–8.44) 0.640
Dose of MP, g 1.90 (1.25–2.90) 0.003
Dose of oral prednisolone was entered as a segmented time dependent
variable as follows: dose at 1 week, 2 weeks, 1 month, 3 months, 6 months
and 12 months
Ethnicity was classified as Caucasian or non-Caucasian
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hypoalbuminaemia can result in increased serum cor-
ticosteroid levels [17] possibly explaining the increased
risk of complications at treatment onset but also the
variability that is often seen between patients.
There is a paucity of information with regards to risk
factors for steroid induced diabetes mellitus develop-
ment in the AAV literature. In transplantation, it is
recognised that early hyperglycaemia following MP and
oral corticosteroid treatment is associated with increased
likelihood of developing new onset diabetes after trans-
plantation [18, 19]. Whilst an early study did not show
an association between the total dose or duration of
intravenous MP and new onset diabetes after transplant-
ation [20], a more recent study has suggested increased
likelihood of new onset diabetes after transplantation
with higher MP doses at the time of transplantation
[21], which is in agreement with our findings. The re-
sponse to MP however may vary across individuals de-
pending on other risk factors such as ethnicity [22]. In
our cohort, although we observed a statistically signifi-
cant difference in ethnicity between MP and non-MP
treated groups, we did not find any effect of ethnicity on
the development of new onset diabetes. However, given
the predominance of Caucasian patients in our cohort,
the study was not adequately powered to detect differ-
ences in new onset diabetes between Caucasians and
other ethnic groups.
In contrast to our findings, a recently published retro-
spective cohort study examining the effect of intraven-
ous pulse MP on renal recovery in Chinese patients
presenting with severe AAV, found that the use of MP
was associated with a lower percentage of patients
remaining dialysis dependent [23]. However, none of the
patients in that study received plasma exchange, whilst
the patient cohort was comprised of a population with a
higher incidence of MPO-ANCA disease and conse-
quently more chronic sclerotic and mixed lesions in
renal pathology compared to Western populations [24,
25]. In addition, patients that did not receive pulse MP
in the Ma et al. study had smaller kidneys on ultrasound
assessment, were less likely to have had a renal biopsy
and might have represented cases of late referral with a
higher burden of chronic and fibrotic changes, poten-
tially accounting for the inferior renal recovery outcome
in non-MP treated patients in that study [23].
The advent of induction of remission treatment strat-
egies based on cyclophosphamide and high-dose cortico-
steroids has transformed AAV from an almost
universally fatal condition to a chronic illness associated
with considerable treatment related morbidity. Indeed
one of the main goals and challenges in the management
of AAV is to minimise treatment related complications
and toxicity without compromising efficacy. Corticoste-
roids remain central in the development of significant
toxicity and current clinical trials [26] are investigating
whether lower intensity corticosteroid regimes may be
equally effective, with an aim of reducing the toxicity
burden associated with steroid use. It must be kept in
mind that 1.5 g of MP, the commonest total dose of
intravenous MP administered over 3 days in the setting
of severe AAV, is equivalent to 1.875 g of oral prednisol-
one or 1 month of high-dose oral prednisolone treat-
ment (60 mg / day).
Conclusions
The MEPEX trial showed that plasma exchange was more
efficacious at 12months compared with pulse MP in pa-
tients with life-threatening renal disease [3]. However, des-
pite no evidence from randomised controlled trials or
indeed contemporary observational data to support this,
pulse MP is commonly used in addition to plasma ex-
change. Our retrospective analysis suggests that addition
of pulse intravenous MP to standard therapy for remission
induction in severe AAV does not confer clinical benefit.
Conversely, MP use was associated with more episodes of
infection and a higher incidence of diabetes. Our data
question the widespread use of pulse MP in the treatment
of severe AAV and indicate the need for an appropriately
conducted randomised controlled clinical trial to defini-
tively answer the question of whether MP should be used
in the treatment of severe AAV and whether there may be
a subgroup of patients in whom treatment with MP may
be advantageous.
Additional file
Additional file 1: Tables S1. Intravenous pulse methylprednisolone use
and dosage. Table S2. Cyclophosphamide and oral prednisolone dose in
intravenous pulse methylprednisolone (MP) and non-MP treated patients.
Table S3. Factors associated with infection at 3 months on univariable
and multivariable proportional hazards analysis. Figure S1. Time to infec-
tion by 3 months (A) and from 3 to 12 months (B) and time to severe in-
fection by 3 months (C) and from 3 to 12 months (D) was examined by
Kaplan-Meier curve analysis. Time to infection for patients that received
MP is shown in the dashed line and that for non-MP treated patients in
the solid line. (DOCX 150 kb)
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